The Complement C1s Subcomponent pipeline drugs market research report outlays comprehensive information on the Complement C1s Subcomponent targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Complement C1s Subcomponent pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Central Nervous System, Hematological Disorders, and Infectious Disease which include the indications Autoimmune Disorders, Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Acquired (Autoimmune) Hemolytic Anemia, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Coronavirus Disease 2019 (COVID-19), and Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome. It also reviews key players involved in Complement C1s Subcomponent targeted therapeutics development with respective active and dormant or discontinued products.
The Complement C1s Subcomponent pipeline targets constitutes close to 12 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 5, 2, 1, 2, and 1 respectively.
Complement C1s Subcomponent overview
Complement C1s subcomponent (C1s) is a serine protease that is part of the classical pathway of the complement system. The complement system is an essential component of the immune system, contributing to the body’s defense against infections and the clearance of damaged or altered cells. C1s plays a crucial role in the activation of the classical pathway.
For a complete picture of Complement C1s Subcomponent’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
